UNLIMITED TURBO BULL - MODERNA | Market Closed - Euronext Paris 12:30:00 2024-06-19 pm EDT | ||
| 6.24 EUR | -4.15% |
|
| Current month | -13.67% | ||
| 1 month | -2.65% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-19 | 6.24 | -4.15% |
| 24-06-18 | 6.51 | -6.33% |
| 24-06-17 | 6.95 | -0.71% |
| 24-06-14 | 7 | -7.77% |
| 24-06-13 | 7.59 | -1.81% |
Real-time Euronext Paris
Last update June 19, 2024 at 12:30 pm EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| 384DS | |
| ISIN | DE000SU1P1H9 |
| Date issued | 2023-11-03 |
| Strike | 64.89 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.82 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.76 € |
|---|---|
| Lowest since issue | 0.645 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Certificates
- 384DS Certificat
